Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute, posted the following on X:
“Interesting insights from our poll on the BREAKWATER trial results. Nearly a quarter of respondents will wait for final OS data before offering Enco+Cetux_FOLFOX routinely for newly diagnosed BRAFV600E mutated CRC.”
